• Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year
• CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to cross the blood-brain barrier to target central nervous system tumors
• CNS’s clinical trial sites have begun enrolling patients in the United States, France, Spain and Switzerland, with sites prepared to receive patients in Italy as well
• CNS has received fast-track and orphan drug recognition for Berubicin from the FDA, helping the company to streamline its path to potential commercialization, and CNS is also preparing to apply for orphan drug designation in the European Union
• CEO John Climaco reported on company developments at the Virtual Investor GBM Spotlight Event on April 4

For decades, medical science has sought an effective means of stopping the most common primary brain cancer in adults in its tracks and keeping it from recurring. In spite of multimodal treatment that includes surgical removal, radiotherapy and chemotherapy, glioblastoma tumors remain the deadliest form of brain cancer and are essentially incurable, leaving patients with a median life expectancy of about 15 months.

The field of contenders for solving this unmet medical need is competitive, with experimental clinical research introducing options that range from using magnetically controlled carbon nanotubes in nanosurgery to immunotherapy to cancer-killing cell therapies.

CNS Pharmaceuticals (NASDAQ: CNSP) is using its novel anthracycline Berubicin in an ongoing, potentially pivotal, global Phase 2 trial that expects to enroll more than 200 patients at sites that currently include clinics in the United States, France, Spain, Switzerland and Italy, with primary completion of the study next year and final results of the study in early 2025 (https://ibn.fm/G7G2w).

Anthracyclines are a class of chemotherapy agents used to treat other cancers for decades, but anthracyclines’ inability to cross the blood-brain cellular barrier to target brain tumors has been a limiting factor in central nervous system ailments.

Berubicin appears to have a unique ability to cross the blood-brain barrier to attack glioblastoma (“GBM”) tumors where they reside, and the ongoing trial is seeking to establish an improvement in the overall survivability (“OS”) of GBM patients using Berubicin. It follows on prior clinical trials that demonstrated the novel anthracycline’s safety in human patients and potential effectiveness against lab cells, as well as evidence of improved OS over the median rate (https://ibn.fm/6y0YZ).

Berubicin is being evaluated as a second-line treatment to stop tumor recurrence following on initial efforts to stop GBMs through surgical removal and targeted radiation therapy to eliminate as much of the cancer as possible. It has been granted fast-track status with Orphan Drug Designation (“ODD”) by the U.S. Food and Drug Administration (“FDA”).

The company is seeking similar ODD status in the European Union, which would grant a decade of IP protection in those countries.

A decrease in the size of GBM tumors, a halt to the growth of tumors, and / or an extension of the time the tumors take to progress will be regarded as favorable outcomes of the trial. When Berubicin was initially developed by Reata Pharmaceuticals in 2006, a small-scale safety study helped establish the drug’s safety but also resulted in one patient emerging cancer-free and nearly half the other patients showing statistical improvement in their conditions, leading CNS Pharmaceuticals to take up the challenge of continuing to test Berubicin’s potential for commercial availability in 2017 (https://ibn.fm/YLnla).

CNS has a strong balance sheet for executing its trial development strategy for achieving clinical and regulatory milestones. The company reported a cash balance of about $7 million in September, which was then supplemented by a $6 million public offering in late November.

CEO John Climaco reported on GBM’s unmet medical need and CNS’s progress in battling it at the Virtual Investor GBM Spotlight Event on April 4, with a live video webcast of the event (https://ir.cnspharma.com/news-events/ir-calendar/detail/2795/virtual-investor-gbm-spotlight-event).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

Thousands of cannabis industry and community members will gather at the Metro Toronto Convention Centre, June 1-3, for three high-energy days of discovery, education, entertainment and more. 

The highly anticipated Lift Toronto 2023 Cannabis Conference and Expo, which will bring together thousands of cannabis industry professionals and consumers from all parts of the cannabis ecosystem, returns to the Metro Toronto Convention Centre from June 1-3, 2023. Hundreds of exhibiting companies will showcase the latest in cannabis products, services and innovations; industry leaders and fresh voices will take the stage; and new experiences and activations will lead to Lift’s signature a-ha moments. Registration is now open, with special “early bird” pricing available for a limited time.

The three-day event kicks off on Thursday June 1 with the Lift Cannabis Business Conference (“LCBC”), an all- business strategy forum focusing on the drivers of forward momentum, overcoming systemic challenges, and advancing innovative business and regulatory solutions that will generate meaningful change and sustainable growth in Canada’s cannabis industry. 

Session highlights from LCBC include: 

• Keynotes & Spotlight Presenters: Priorities & Progress of Canada’s Cannabis Industry, Fairness in Banking, and What the CannTrust Case Taught Us
• Canada’s Brands & World View Leadership Panels: Bullish and Bearish, New and Established, International Markets and How to Remain Competitive and Grow
• Legacy Consumers to Legal: What the Illicit Market Can Teach the Legal Market
• Plus: Winning Confidence of Lenders & Investors; The Growth of Extracts, Concentrates & Processing; and (Caged) Guerrilla Cannabis Marketing.

With An Outstanding Roster of Speakers: Anna-Sophia Kouparanis, Co-Founder, Bloomwell Group (Germany) | Guillermo Delmonte, Founder, NDLATAN (Uruguay) | Niel Marotta, CEO & Founder, INDIVA | Brishna Kamal, President, Whistler Therapeutics | John Fowler, CEO, Muskoka Grown | David Goldstein, CEO, Stoke Inventory Partners | Mike Schilling, CEO, Community Savings Credit Union | Katy Perry, CEO, TOKE Cannabis | Adam Temple, CEO, Evolved Extraction Solutions | Andrew Fischer, CEO, Protonify | Dave Marino, President, Spirit Leaf Ontario & Superette Ontario 

“We are really pushing the envelope for our next trip to Toronto with top-tier presenters on red hot topics,” says Barry Smith, Canadian Content Director, Lift Events & Experiences. “Each session has been carefully curated to energize, inspire, educate and motivate all of our audiences from across the entire cannabis community.” 

On Friday, June 2, Industry & Budtender Day will feature multiple stages with individually-crafted content to inform and spark conversations that will drive the industry forward in the coming year. Saturday, June 3, is Consumer Day, open again to industry members and budtenders, as well as everyone from the canna-curious to the canna-connoisseur. 

Session highlights from the Expo floor include: 

• Budtender Masterclass: Product knowledge, retail operations and new harm reduction toolkit. 
• Maestros of Marketing: Power panel featuring key brand and retail players. 
• Unforgettable Edibles & Beverages: New tastes for fun and relaxation. 
• Diversity Dividend: The bottom-line benefits and just good policy. 
• Cannabis Tourism Spotlight: Everything about leisure, lounges and adventures. 
• Craft Cannabis: Hitting new highs, one small batch at a time. 
• & so much more!

In addition, on both Friday and Saturday, the Lift expo floor will showcase a wide array of leading and emerging exhibitors while debuting fresh experiences, education and activations including: 

• The Diner’s Club: Don’t miss the hottest culinary cannabis trends and insights. 
• Morning Mic-Drop: A laugh out loud comedy performance from The Noobie and The Doobie, Timmy Boyle & Marijane Baker. 
• PLAY@Lift: Enjoy games, photo opps, sweets and more. 
• Outdoor Networking Lounge: The place to be for a catch-up sesh. 
• Brand Discovery Zone: See what’s new with your favorite and emerging brands. 
• Budtender Lounge: A dedicated area to mix and mingle with your colleagues. 
• Lift After Party: Enjoy live music, drinks, bites and networking to end the show on a high note. 

Event Schedule 

Lift Cannabis Business Conference | Thursday, June 1, 2023 | 9 a.m. – 5 p.m.

Lift Expo Industry Days | Friday, June 2 and Saturday, June 3, 2023 | 11 a.m. – 5 p.m. 

Lift Expo Consumer Day | Saturday, June 3, 2023 | 11 a.m. – 5 p.m. 

Click to view ticket types and pricing 

Up Next:
Lift San Francisco: August 2-4, 2023 | Moscone Convention Center
San Francisco speaker applications are open, and exhibits and partnerships are now available. Registration for Lift San Francisco will open later this spring. 

For more information or to schedule an interview, contact Sacha Cohen at 202-251-9417 or sacha@themaverickpr.com

About Lift

Lift Events & Experiences serve the cannabis community as both a meeting place and a destination for discovery. With dates across North America, each Lift event showcases leading-edge content and premiere exhibitors in a high-energy setting for thousands of cannabis growers, processors, manufacturers, brands, budtenders, retail

• SideChannel is a cybersecurity services company driven by a stated mission to make cybersecurity simple, accessible, effective, and affordable
• The company targets small and mid-sized businesses that are often priced out of quality cybersecurity services
• SideChannel’s services include vCISO services, vCPO services, risk assessment, cybersecurity compliance, and third-party risk management
• By providing these services, the company empowers clients to reduce risks, balance their security and privacy services investment, and build the confidence needed to operate with business-aligned security and privacy

SideChannel (OTCQB: SDCH), a company focused on addressing cybersecurity challenges for mid-market companies, startups, and small enterprises normally priced out of quality services, is driven by the mission to make cybersecurity work for small and mid-size operations. This is especially timely given the increased complexity of cyber threats, rapidly changing technology, and fast-evolving industry best practices. The company, through its team of cybersecurity experts, affordably delivers highly tailored services that reduce cyber risk, maximize investments, and give client organizations the confidence needed to achieve their objectives.

“Where we step in is identifying and knowing what can slow [attackers] down; what can stop them; [and] what can be built at an organization that allows you to feel much better about your cybersecurity posture in addressing risks, regulatory concerns, and the questions from your board or C-suite, and being able to put your customers’ at ease that you have a cybersecurity program,” remarked SideChannel CEO Brian Haugli during the company’s Investor Day presentation (https://ibn.fm/SFBsm).

Haugli’s statement introduces the company’s suite of services that includes (a) virtual Chief Information Security Officers (“vCISOs”); (b) virtual Chief Privacy Officers (“vCPOs”); (c) risk assessments; (d) cybersecurity compliance; and (e) risk management. These services, SideChannel’s services webpage highlights, are designed for the unique needs and objectives of small and mid-sized businesses (“SMBs”) and are strategically delivered as a result of the company combining an innovative and comprehensive approach with in-house expertise. This expertise takes the form of highly experienced vCISOs and vCPOs.

When a client contracts SideChannel, the company assesses the business’s needs and objectives and then pairs it with a vCISO or vCPO who works remotely (hence the ‘virtual’ prefix) with the client’s team as an extension. If the client is paired with a vCISOs, for example, this professional first establishes the prevailing security posture. Next, they identify gaps and challenges and collaborate with the client’s team and stakeholders to create a comprehensive and actionable security strategy that enables the business to maintain an effective and lasting cybersecurity program (https://ibn.fm/a0fd4). The vCISOs also understand what it takes to secure compliance and lend this knowledge to the client, helping them comply with state and federal regulations and safeguards, if need be (https://ibn.fm/X4cps).

In cases where the client is paired with a vCPO, this professional identifies the organization’s current privacy posture, pinpoints gaps and challenges, and works collaboratively with the client’s employees to develop a comprehensive and actionable security strategy that helps the organization maintain an effective and lasting privacy program (https://ibn.fm/Ntufu).

The similarity in how the vCISOs and vCPOs execute their responsibilities is not an inadvertent error. Instead, it stems from a shared methodology specifically designed to help them assess security or privacy risks.  The risk assessment methodology’s first step involves understanding an organization’s current profile – posture – by assessing threats, assets, strengths, weaknesses, partners, regulatory obligations, and investments through SideChannel’s research of proprietary data sources and talking to the client’s team.

Next, the vCISOs and vCPOs test relative operational and program effectiveness through scenario analysis and walkthroughs in what is designed to measure the organization’s controls and build a full understanding of its current posture and outlook. To boost transparency and clarity, the professionals deliver data-driven progress reports that aim to communicate the findings uncovered throughout this stage. Finally, the vCISOs and vCPOs develop an actionable plan that may include program, policy, and procedure documentation; strategy development; procurement and vendor negotiation; identification, implementation, and management of tools; oversight of team and program activities; and testing the capabilities (https://ibn.fm/llirI).

In executing their duties, SideChannel’s professionals draw from their years of experience, with vCISOs having previously worked at reputable organizations as CISOs and Chief Security Officers (“CSOs”) and the vCPOs having previously held privacy and legal roles in large organizations. Collectively, SideChannel’s team comprises the best and brightest from the cybersecurity and privacy industries.

Beyond risk assessments, SideChannel provides third-party risk management services that protect its clients from threats and risks born out of working with other parties. “With third-party risk management services, we help effectively respond to third-party risk assessment questionnaires and conduct third-party risk assessments of your vendors, ensuring that critical data is secure,” the company’s website explains (https://ibn.fm/2WVjv).

Ultimately, and by providing these services, SideChannel aims to help its clients reduce risks, balance their security and privacy services investment, and build the confidence needed to operate through business-aligned security and privacy.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• GeoSolar’s SmartGreen(TM) whole-home renewable energy system potentially reduces dependence on fossil fuels while lowering or even completely eliminating utility bills
• The SmartGreen(TM) system includes photovoltaic solar panels, geothermal ground loops, integrated air ducts and floor loops, CERV(R) air filtration, upgrades to lighting systems, windows, insulation
• The SmartGreen(TM) system can be integrated into new construction projects or existing buildings
• GeoSolar plans to market SmartGreen(TM) to over 120 million homes across the U.S. with various financing options, tax deductions, utility incentives

The Intergovernmental Panel on Climate Change (“IPCC”) has stated that there is over a 95% probability that the observed warming of the Earth’s surface since the mid-20th century is being caused by human activities (https://ibn.fm/KhSzI). Global policies aimed at reducing carbon emissions include carbon pricing initiatives that incentivize reduced carbon footprints, energy efficiency standards, renewable energy incentives, and international agreements.

GeoSolar Technologies (“GST”) is committed to enabling a carbon-free future with their SmartGreen(TM) Home system — a whole home renewable energy system that helps homeowners reduce or eliminate carbon use while saving money and achieving energy independence.

SmartGreen(TM) is an integrated whole-home technology system that uses rooftop solar panels to generate electricity, geothermal ground loops to heat and cool the home, and CERV(R) air filtration to maintain optimal air quality. The system can be adapted to both new construction and existing buildings, and includes upgraded windows, insulation, and lighting.

According to the Company, the SmartGreen(TM) system can reduce or completely eliminate utility bills, provide homeowners energy independence, decrease carbon emissions by approximately 8 tons per home annually, and increase the home’s value. The Company also believes that with the adoption of a SmartGreen(TM) home supports the renewable energy industry and can lead to the creation of jobs in a decarbonized future.

GeoSolar Technologies is committed to making the SmartGreen(TM) system accessible and affordable through various financing options, tax deductions, and utility incentives. With a plan to market the system to over 120 million homes across the United States, GeoSolar aims to revolutionize the residential energy industry while reducing carbon pollution by an estimated 1.9 trillion pounds per year (https://ibn.fm/shOUe).

In addition, GeoSolar Technologies is conducting a Reg A+ capital raise to give everyone an opportunity to invest in the company and own a part of the SmartGreen(TM) system for as little as $300.

For more information on GeoSolar’s Regulation A+ capital raise, please visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• CNS Pharmaceuticals recently announced it had enrolled the first patient in Switzerland as part of its ongoing potentially pivotal global GBM trial
• The adaptive, multicenter, open-label, randomized controlled trial is evaluating Berubicin for the treatment of recurrent GBM, the most common primary brain cancer, compared to Lomustine, the current standard of care
• The enrollment moves the company closer to its goal of undertaking an interim analysis expected in the third quarter of 2023
• So far, CNS Pharmaceuticals has opened over 40 of 59 planned clinical trial sites selected across Switzerland, Spain, France, Italy, and the U.S.
• As an aside, the company announced it does not hold any deposits or investments at the now-collapsed Silicon Valley Bank (“SVB”)

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently reported the enrolment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”) (https://ibn.fm/60iyl).

An aggressive, fast-growing primary brain tumor, GBM accounts for 45.2% of primary malignant brain and central nervous system (“CNS”) tumors, making it the most common primary brain cancer. Unfortunately, GBM has largely remained an incurable disease with a poor prognosis – it has a median survival of 15 months, and only 5.5% of the patients survive to the fifth year after diagnosis. In the intervening period, the patients usually experience symptoms such as memory problems, personality changes, vision and language difficulties, headaches, seizures, and even paralysis as the tumor grows, exerting pressure on surrounding brain cells (https://ibn.fm/gsAoV).

To preserve neurological function, reduce the chances and instances when the patients experience the aforementioned symptoms, and improve survival, safe surgical resection is preferred, following which the patients undergo radiotherapy and chemotherapy. This set of treatments – surgery followed by radiotherapy and chemotherapy- is the standard first-line therapy. Often, however, given the disease’s aggressive nature, GBM has a high rate of recurrence, even after completion of first-line therapy.

For this reason, CNS Pharmaceutical’s adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. In addition, the study will also enroll patients who have received additional treatments as part of the first-line therapy in recognition of the complexity of new agents introduced as a component of this therapy.

The study will compare Berubicin, a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, to Lomustine, the current standard of care (“SOC”). More specifically, it will assess the effect of Berubicin compared with Lomustine on Overall Survival (“OS”), its primary endpoint measure, one that is recognized by the Food and Drug Administration (“FDA”) as the basis for approval of oncology drugs.

In the meantime, before completing assessments on all enrolled participants, CNS Pharmaceuticals aims to undertake an interim analysis expected sometime in the third quarter of 2023. This pre-planned, non-binding futility analysis will include additional evaluation of safety and secondary efficacy endpoints.

Thus, the latest enrollment continues the company’s progress toward the interim analysis. It follows a February 7 announcement that the first patient in Spain had been enrolled (https://ibn.fm/QBPv2). Moreover, late last year, on November 2, CNS announced the enrollment and dosing of the first patient in France (https://ibn.fm/fNx2S). As a result of this expanded enrollment, CNS Pharmaceuticals has so far opened over 40 out of 59 clinical trial sites selected across Switzerland, Spain, France, Italy, and the U.S.

“The active enrollment we continue to build across our clinical trial sites in Europe is incredibly encouraging. Our team is laser focused on getting additional clinical trial sites online so that we can continue to advance toward our planned interim analysis,” John Climaco said of the latest enrollment in Switzerland.

Meanwhile, CNS Pharmaceuticals also reported it does not hold any deposits or investments at Silicon Valley Bank (“SVB”) (https://ibn.fm/2rwIo). SVB was on March 10 closed by the California Department of Financial Protection and Innovation, signaling its collapse, with the Federal Deposit Insurance Corporation (“FDIC”) subsequently appointed receiver and assuming control of the bank (https://ibn.fm/y1fMD).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Reflex Advanced Materials has begun the qualification process and boasts established relationships with more than 25 key North American customers, putting it years ahead of the competition in the lengthy graphite sales cycle
• The company has executed two critical product development and material research partnerships in an effort to diversify risk and improve margins
• Reflex Advanced Materials expects to begin fulfilling major graphite orders in 2024, with supply, processing partners and demand already in place
• The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles, and the company has identified its Ruby Graphite Project as a ‘prime candidate’ for U.S.-sponsored initiatives
• A rise in anode demand is expected to fuel a shortage of 8 million tonnes by 2040, with World Bank Group projecting 494% growth in graphite demand by 2050

Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.

Projects

Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (“CSPG”) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

For more information, visit the company’s website at www.ReflexMaterials.com.

NOTE TO INVESTORS: The latest news and updates relating to RFLXF are available in the company’s newsroom at https://ibn.fm/RFLXF

• Coyuchi’s line of gold-standard luxury home goods includes bedding, sheets, towels, apparel, and other home goods made using 100% organic cotton
• The organic bedding market was valued at $836.4 million in 2020, and is expected to grow at a CAGR of 5.1%, resulting in a value of $1.1 billion by 2025
• Coyuchi’s Bedroom Inspiration is uniquely designed to calm, revitalize, and build a mindfully made mood within an end user’s personal organic sleeping space

At the forefront of consumer organic home products is Coyuchi, a gold standard in sustainable luxury home goods, including bedding, sheets, towels, apparel, and other home items made using 100% organic cotton. Bedding is one of the most personal such items, since we spend a significant portion of each day in close contact with it. Conventional bedding is often made using processes that require deep chemical treatments, and these treatments can cause the skin to feel itchy or cause other dermatological problems. The rising awareness of conventional fiber treatment methods has caused an increase in demand for more natural, sustainable alternatives. Because of this, the organic bedding market is expected to rise at a CAGR of 5.1% to reach $1.1 billion by 2025, compared to $836.4 million in 2020 (https://ibn.fm/yCszf).

Coyuchi’s timeless, coastal-inspired aesthetic caters to environmentally-conscious consumers looking to throw out conventional bedding and replace it with a bedding collection designed to calm, revitalize, and build a mindfully made mood within their organic sleeping space (https://ibn.fm/IKxM8). Coyuchi’s Bedroom Inspiration includes unique stitching, patterns, and colors that are indicative of the surrounding coastal-inspired landscape:

• Coastal Gingham Collection
• Channel Handstitched Collection
• Seascape Collection
• Geo Cove Collection
• Crinkled Percale(TM) Collection
• Toro Canyon Collection
• Rippled Stripe Collection
• Cascade Collection
• Ashbury Collection
• Avila Collection
• Pebbled Handstitched Collection
• Sonoma Collection
• Diamond Stitched Collection
• Manzanita Collection
• Noe Collection
• Morelia Collection
• Precita Collection

For those who want to get started with organic bedding from Coyuchi, the Bedding Basics collection provides the easiest way to update your bedding to organic. The line features the organic latex Turiya Pillow, Three Season Down Duvet Insert, mattress pad, and down pillow, each sold separately.

Led by Eileen Mockus, president and CEO of Coyuchi, the company was built on four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. For 30 years, Coyuchi has been exploring organic farming and sustainable textiles, guaranteeing the highest environmental and ethical standards through many certifications, such as The Global Organic Textile Standard (“GOTS”), Fair Trade Certified, and MADE SAFE(R).

Coyuchi continues to push the organic textile market forward without sacrificing the planet’s health, resulting in several important sustainability checks and balances. These include the company’s holistic 360-degree approach to fighting climate change through its take-back and recycling program, 2nd Home(TM), the Coyuchi Climate Council with the goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030, and C4 (The California Cotton & Climate Coalition ) which includes brands like MATE the Label, Outerknown, Reformation, and Trace, all working together to invest in regionally grown, Climate Beneficial(TM) cotton and to directly support the livelihoods of the farmers growing it.

Coyuchi’s growing product assortment comprises about 1,400 SKUs of consciously designed products, providing the company a significant competitive advantage. Coyuchi upholds the Global Organic Textile Standards (“GOTS”) certification for all its cotton. GOTS is the world’s leading textile processing standard for organic fibers. It ensures the organic status of textiles after harvesting raw materials through environmentally responsible manufacturing to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi is currently accepting investment as part of a Regulation A+ offering. For more information, visit the company’s profile on Manhattan Street Capital (https://ibn.fm/gjM4P) and review its Offering Circular (https://ibn.fm/Z1P0i).

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• Massachusetts-headquartered cybersecurity services and technology provider SideChannel Inc. has dedicated itself to serving SMB companies who may be unable to employ on-staff cyber risk management personnel, delivering expertise on contract instead
• SideChannel recently bolstered its “virtual” chief information security officer (“vCISO”) service by partnering with automated supply chain risk management platform developer Darkbeam, a London-based company similarly focused on client cyber security
• Darkbeam’s platform provides tools for clients to do data dives on affiliated domains and monitor changes in their security status by analyzing a “Cyber Intelligence Quotient”
• SideChannel also offers clients a microsegmentation tool as a software-as-a-service (“SaaS”) subscription product, which the company also can operate as a managed service if clients prefer

Businesses have enough challenges managing their potential vulnerability to cyber attacks dwithout having to worry about the cyber risk of other companies involved in their supply chain as well.

Cybersecurity services and technology provider SideChannel (OTCQB: SDCH) announced recently that it is partnering its virtual chief information security officer (“vCISO”) expertise with London-based cyber intelligence provider Darkbeam’s advanced risk management platform to grant clients greater tools for preventing losses due to attacks on their computer data infrastructure — both internally and across the breadth of their supply chains.

Darkbeam CEO Charles Clark spoke of the advantages of the partnership in the companies’ news release, stating, “We are delighted to couple our powerful Cyber Risk Management platform with SideChannel’s significant leadership expertise and toolset. … By joining forces, we can provide a comprehensive solution that empowers organizations to proactively manage cyber risks and safeguard their operations, which means our clients can spend less energy worrying about defending themselves and more energy delivering the things that make them great” (https://ibn.fm/HvjtI).

Darkbeam’s automated platform creates on-demand audits in seconds for different domains, allowing companies to assess their suppliers’ digital risk through deep data analysis. Clients can track the Cyber Intelligence Quotient (Cyber IQ) of pertinent domains over time and will soon be able to receive instant notification of any changes to that Cyber IQ.

Darkbeam’s platform checks for exposed and breached emails using the specific domain, using over 50 unique approaches for vulnerabilities.

“Partnering with Darkbeam enables us to deliver even more value to our clients, ensuring them access to the most advanced tools to assess their risk exposure, predict future vulnerabilities and respond to emerging threats,” SideChannel CEO Brian Haugli stated in the news release.

SideChannel is dedicated to helping small and medium-sized businesses (“SMBs”) bolster their cybersecurity even when they may lack the budget necessary to employ a CISO full-time on staff. SideChannel’s virtual CISO service provides contracted CISO expertise through personnel who can embed themselves in company boardrooms alongside the clients’ leading officers.

“We can deliver an entire program and manage that for the mid-market, because that’s how the mid-market buys. That’s what they’re looking for,” Haugli said during a live company webcast in February (https://ibn.fm/5qWZo). “They really want, not just the tools, they don’t want just the capability and then (for us to) walk away. They want a partner who can come in and manage and run that for them.”

SideChannel also provides a microsegmentation resource called Enclave to clients who want to operate their own security system, however, on a software-as-a-service (“SaaS”) subscription basis.

“We’re going to continue to develop around Enclave, adding new features and capabilities that make sense for how Enclave is structured — based … on what we’re seeing in our clients, what we’re hearing from our CISOs and what types of attacks or attack surface is out there,” Haugli said.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• D-Wave has worked on quantum hybrid applications with commercial customers including industry leaders like Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin
• The company’s intellectual property portfolio includes more than 210 issued US patents and more than 100 peer-reviewed papers in leading scientific journals
• D-Wave’s customer success stories showcase the company’s quantum computing technology in action

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, focused on delivering value to customers via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection, and financial modeling, showcases the tangible value of its practical quantum computing solutions through its customer success stories.

D-Wave has worked with commercial customers include blue-chip industry leaders like Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin, in addition to others. The company owns one of the industry’s largest quantum computer intellectual property portfolios, boasting more than 210 issued US patents, and has published more than 100 peer-reviewed papers in leading scientific journals.

Testimonials from D-Wave customers, highlighted in a dedicated video on the company’s website, showcase real-life use cases of D-Wave’s quantum computing solutions being used to address a variety of problems ranging from grocery optimization to protein design (https://ibn.fm/8R769). In addition, several customers joined D-Wave on stage at the Qubits user conference in January, showing live demos of the quantum-hybrid applications built on D-Wave technology (https://ibn.fm/lKsjm).

“Using hybrid quantum applications, we’re able to solve astronomical protein design problems,” said Hans Melo, Ph.D., co-founder and CEO of Menten AI, featured in the customer video and an individual case study report (https://ibn.fm/ktCyC). “We’ve seen extremely encouraging results, with hybrid quantum procedures often finding better solutions than competing classical solvers for de novo protein design. This means we can create better proteins and ultimately enable new drug discoveries.”

The advances in computing technology have allowed companies like Menten AI to begin transforming the protein design process. Through D-Wave’s hybrid solver, Menten AI produced several different peptide designs from scratch, made with both natural and non-natural amino acids – creating an expansion of the fundamental building blocks of life beyond those used in nature up until now.

Pattison Food Group integrated D-Wave’s quantum technology to provide optimization that aligns with its complex business constraints to decrease costs, improve performance, and improve customer experience. So far, the company has seen a reduction in time spent solving these problems from 25 hours to seconds, has reduced turnaround time from idea to design in two months, and has started applying quantum in daily production by embedding it seamlessly into its business solutions (https://ibn.fm/cDilm).

When the pandemic created myriad disruptions and logistical challenges for organizations, Tokyo-based startup Sigma-i collaborated with D-Wave to develop a quantum computing-based solution to circumvent these problems for businesses, schools, hospitals, and more. The parameters of the New Normal Scheduler were easily optimized as operating conditions changed – shifts in remote work, accounting for holidays, or other interruptions in the work week. Once fed the relevant information, D-Wave’s hybrid solver service produced an optimized work schedule in a matter of seconds (https://ibn.fm/hjhC2).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications
• Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes
• Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active pharmaceutical ingredients (“APIs”). Lexaria’s patented DehydraTECH(TM) technology is a formulation and dehydration processing procedure that changes how the body detects and absorbs drugs. The company currently has 28 granted patents, with many more pending patents in countries worldwide.

Lexaria specifically designed DehydraTECH for formulating and delivering topical or oral lipophilic (fat-soluble) drugs and APIs to increase effectiveness and improve how they enter the bloodstream. The major benefits of a DehydraTECH-enabled drug or consumer product include the following:

• Faster delivery time – the effects of the product are felt by the subject in minutes
• Increased bioavailability – the technology is more effective at delivering a drug or product into the bloodstream
• Increased brain absorption –testing suggests significant improvement in the quantity of the drug or product delivered across the blood-brain barrier
• Improved drug potency – more of the drug or product is made available in the body, requiring lower dosages for the desired outcome
• Reduced drug administration costs – lower dosages mean lower overall drug costs
• Improved taste – the technology eliminates the necessity for sweeteners to eliminate or reduce unwanted taste

One of Lexaria’s studies is cannabidiol (“CBD”) for hypertension, which has produced positive results for the company to seek Investigational New Drug (“IND”) status with the United States Food and Drug Administration (“FDA”). The company has completed a pre-IND meeting and intends to file for IND status in 2023. Lexaria’s first and subsequent DehydraTECH-CBD human studies have shown superior human blood absorption levels and demonstrated a potential novel mechanism of action in reducing blood pressure. More information on Lexaria’s current studies can be found on the company’s fact sheet (https://ir.lexariabioscience.com/presentations).

The global non-prescription CBD market was valued at $4.9 billion in 2021 and is expected to reach $47.22 billion in 2028, growing at a CAGR of 21.3% (https://ibn.fm/4Ldss). There has also been increased product acceptance and use due to FDA approval of one type of CBD. CBD is being studied in a variety of medical applications worldwide, including anxiety and depression treatment, stress reduction, diabetes prevention, pain relief, cancer symptom relief, and inflammation relief. Lexaria is currently exploring DehydraTECH-CBD-enabled formulations for hypertension, epilepsy, diabetes and dementia indications.

Since 2016, Lexaria’s DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption, reduce onset time from hours to just minutes, and mask unwanted tastes. The company intends to further evaluate the technology for other oral and topical use potential in cannabinoids, oral nicotine and other APIs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX